Should Molecular Genetics Guide the Decision for Allogeneic Transplant? - Con

Classically, the indication and timing of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with myelodysplastic syndromes (MDS) is based on the individual risk score obtained by applying the original International Prognostic Scoring System (IPSS) or its recently revised version (IPSS-R).1-3 Those scoring systems use three disease-related characteristics: chromosomal abnormalities, percentage of blast cells in bone marrow, and number and severity of cytopenias.1,2 Allo-HCT at diagnosis is recommended for higher-risk patients whereas transplantation for lower-risk MDS is usually delayed until there are signs of disease progression.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research